FDA Clears Medicus to Start Gorlin Syndrome Drug Study
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) received U.S. Food and Drug Administration authorization to begin a registrational Phase 2b study of its SkinJect treatment in patients with Gorlin …
FDA Clears Medicus to Start Gorlin Syndrome Drug Study Read More